TG Therapeutics (NASDAQ:TGTX – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for TG Therapeutics and Pyxis Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
TG Therapeutics currently has a consensus price target of $63.00, suggesting a potential downside of 1.96%. Pyxis Oncology has a consensus price target of $8.71, suggesting a potential upside of 434.62%. Given Pyxis Oncology’s higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than TG Therapeutics.
Institutional and Insider Ownership
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
TG Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
Profitability
This table compares TG Therapeutics and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TG Therapeutics | 11.81% | 18.52% | 8.03% |
| Pyxis Oncology | N/A | -252.36% | -120.63% |
Earnings and Valuation
This table compares TG Therapeutics and Pyxis Oncology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TG Therapeutics | $897.76 million | 10.96 | $447.18 million | $0.66 | 97.36 |
| Pyxis Oncology | $13.86 million | 9.81 | -$79.62 million | ($1.30) | -1.25 |
TG Therapeutics has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
TG Therapeutics beats Pyxis Oncology on 11 of the 14 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue. Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
